Healthy Returns: First Ozempic generics in Canada will be a test case for Novo Nordisk

AI Summary

The introduction of Ozempic generics in Canada is expected to challenge Novo Nordisk's international revenue from their semaglutide product lines. The development may impact the broader health market significantly.

New generics in Canada likely mark the start of a decline in international revenue of semaglutide, the active ingredient in Novo's Ozempic and Wegovy.